Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.63 |
| ▸ | MAPT | P10636 | 8/20 | 0.63 |
| ▸ | MEN1 | O00255 | 7/20 | 0.63 |
| ▸ | LMNA | P02545 | 6/20 | 0.63 |
| ▸ | GAA | P10253 | 5/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | XBP1 | P17861 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | HTT | P42858 | 4/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1167631 | 0.84 | KMT2A (0.63) | KMT2AMAPTMEN1LMNAGAA | |
| SCHEMBL617270 | 0.81 | KMT2A (0.62) | KMT2AMAPTMEN1LMNAGAA | |
| SCHEMBL1167966 | 0.81 | KMT2A (0.65) | KMT2AMAPTMEN1LMNAGAA | |
| SCHEMBL412113 | 0.80 | MAPT (0.64) | KMT2AMAPTMEN1LMNAGAA | |
| SCHEMBL30203856 | 0.79 | KMT2A (0.67) | KMT2AMAPTMEN1LMNAGAA | |
| SCHEMBL22672258 | 0.79 | KMT2A (0.67) | KMT2AMAPTMEN1LMNAGAA | |
| SCHEMBL617798 | 0.77 | KDM4E (0.45) | KMT2AMAPTMEN1LMNAGAA | |
| SCHEMBL618563 | 0.76 | ERN1 (0.42) | KMT2AMAPTMEN1LMNATDP1 | |
| SCHEMBL616413 | 0.75 | MAPT (0.46) | KMT2AMAPTMEN1LMNAGAA | |
| SCHEMBL615990 | 0.74 | MAPT (0.49) | KMT2AMAPTMEN1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966172-B1 | THIAZOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2014-01-08 | — | — | EP | disclosed |
| EP-1966172-B1 | THIAZOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN (US) | 2013-08-08 | — | — | US | disclosed |
| US-8399435-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399435-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399435-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20090270353-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN | 2009-10-29 | — | — | US | disclosed |
| US-20090270353-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN | 2009-10-29 | — | — | US | disclosed |
| US-7572821-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572821-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572821-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1966172-A1 | THIAZOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Synta Pharmaceuticals Corporation (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070179159-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-08-02 | — | — | US | disclosed |
| US-20070179159-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-08-02 | — | — | US | disclosed |
| US-20070179159-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-08-02 | — | — | US | disclosed |
| WO-2007061909-A1 | THIAZOLES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179159-A1 | Compounds for the treatment of proliferative disorders | RB1, MKI67, MAPRE1 | KMT2A 2808/4885MAPT 95/4885MEN1 1571/4885 |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | KMT2A 2808/4885MAPT 95/4885MEN1 1571/4885 |
| US-20090270353-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | KMT2A 2808/4885MAPT 95/4885MEN1 1571/4885 |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | KMT2A 2808/4885MAPT 95/4885MEN1 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.